Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7795081 PK with Itraconazole, Gemfibrozil, and Cyclosporine in Healthy Participants
NCT06809608Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RO7795081 in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Roche. Primary endpoints: Maximum Concentration Observed, Time to Maximum Concentration Observed and 2 more. Started Feb 2025; status: completed.
02
Drugs
RO7795081
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06809608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06809608.